- Home
- NA vs OCX Comparison
NA vs OCX Comparison
Compare NA & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- OCX
- Stock Information
- Founded
- NA 2019
- OCX 2009
- Country
- NA China
- OCX United States
- Employees
- NA N/A
- OCX N/A
- Industry
- NA Semiconductors
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NA Technology
- OCX Health Care
- Exchange
- NA Nasdaq
- OCX Nasdaq
- Market Cap
- NA 32.3M
- OCX 38.7M
- IPO Year
- NA 2022
- OCX N/A
- Fundamental
- Price
- NA $8.76
- OCX $2.20
- Analyst Decision
- NA
- OCX Buy
- Analyst Count
- NA 0
- OCX 3
- Target Price
- NA N/A
- OCX $4.42
- AVG Volume (30 Days)
- NA 240.6K
- OCX 112.4K
- Earning Date
- NA 09-18-2024
- OCX 11-12-2024
- Dividend Yield
- NA N/A
- OCX N/A
- EPS Growth
- NA N/A
- OCX N/A
- EPS
- NA N/A
- OCX N/A
- Revenue
- NA $6,991,446.00
- OCX $709,000.00
- Revenue This Year
- NA N/A
- OCX N/A
- Revenue Next Year
- NA N/A
- OCX $106.34
- P/E Ratio
- NA N/A
- OCX N/A
- Revenue Growth
- NA N/A
- OCX N/A
- 52 Week Low
- NA $2.75
- OCX $1.98
- 52 Week High
- NA $47.50
- OCX $3.82
- Technical
- Relative Strength Index (RSI)
- NA 52.67
- OCX 29.70
- Support Level
- NA $6.67
- OCX $2.33
- Resistance Level
- NA $10.42
- OCX $2.48
- Average True Range (ATR)
- NA 1.94
- OCX 0.16
- MACD
- NA -0.18
- OCX -0.01
- Stochastic Oscillator
- NA 29.07
- OCX 39.29
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.